Today: 23 April 2026
Subscribe
Browse Category

NYSE:NVL 7 October 2025 - 11 February 2026

Ford supplier Novelis targets June repair for fire-hit Oswego aluminum plant as quarterly loss widens

Ford supplier Novelis targets June repair for fire-hit Oswego aluminum plant as quarterly loss widens

Novelis reported a $160 million fiscal Q3 loss after two fires at its Oswego, New York, aluminum plant cut shipments by 11%. Repairs are expected to finish by end-June, but Ford said full operations may not resume until as late as September, affecting F-150 production costs. Novelis estimated fire-related repair costs at $255 million. No injuries were reported.
11 February 2026
··
Ford Stock Plunges as Devastating Supplier Fire and Recalls Turn 2025 Into a Nightmare

Ford Stock Plunges as Devastating Supplier Fire and Recalls Turn 2025 Into a Nightmare

A Sept. 16 fire destroyed Novelis’s Oswego, NY aluminum plant, threatening Ford’s F-Series production and wiping 7% off Ford’s stock. Analysts estimate an $800 million hit to 2025 earnings. Ford faces record recalls in 2025, including 1.9 million vehicles for faulty cameras, and its EV unit lost $1.3 billion in Q2 as U.S. EV sales dropped 31%. Q3 U.S. sales rose 8.2%, but outlook remains uncertain.
7 October 2025
··

Stock Market Today

  • Altimmune Eyes 2026 Catalysts with Pemvidutide Trials and Funding Concerns
    April 23, 2026, 2:57 PM EDT. Altimmune (ALT) centers its 2026 outlook on pemvidutide, a dual receptor agonist targeting metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder, and liver disease. Key catalysts include the phase II RECLAIM study top-line data on alcohol use disorder expected in Q3 2026 and the planned pivotal phase III start for MASH. Success in these trials could broaden pemvidutide's market potential and shift investor sentiment. Altimmune's distinctive "liver first" approach focuses on combining glucagon and GLP-1 pathways to reduce liver fat and inflammation while supporting weight loss, addressing a competitive space seeking durable liver benefits beyond weight reduction. Financing risks remain a key concern amid evolving clinical development. Investors watch closely as late-stage execution and trial outcomes will influence Altimmune's valuation and future positioning.

Latest article

ServiceNow stock tumbles despite Q1 beat and higher 2026 outlook

ServiceNow stock tumbles despite Q1 beat and higher 2026 outlook

23 April 2026
ServiceNow shares dropped 18.7% to $83.77 after reporting first-quarter results that beat estimates and raising its 2026 subscription revenue forecast. Investors focused on delayed Middle East government deals, which cut subscription growth by 0.75 percentage point, and concerns over AI’s impact on software demand.
IBM Stock Tumbles After Earnings Beat as Software Slowdown Reignites AI Fears

IBM Stock Tumbles After Earnings Beat as Software Slowdown Reignites AI Fears

23 April 2026
IBM shares fell 9.6% to $227.72 after first-quarter results showed slowing software and consulting growth, despite beating earnings estimates. The selloff spread to ServiceNow, Microsoft, and Adobe, while chip stocks rose. IBM reported $15.92 billion in revenue, up 9%, and raised its quarterly dividend to $1.69. Investors reacted to concerns over AI’s impact on older software businesses.
Go toTop